These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 7852188)
1. Prognostic significance of p53 and ras gene abnormalities in lung adenocarcinoma patients with stage I disease after curative resection. Isobe T; Hiyama K; Yoshida Y; Fujiwara Y; Yamakido M Jpn J Cancer Res; 1994 Dec; 85(12):1240-6. PubMed ID: 7852188 [TBL] [Abstract][Full Text] [Related]
2. A universal method for the mutational analysis of K-ras and p53 gene in non-small-cell lung cancer using formalin-fixed paraffin-embedded tissue. Sarkar FH; Valdivieso M; Borders J; Yao KL; Raval MM; Madan SK; Sreepathi P; Shimoyama R; Steiger Z; Visscher DW Diagn Mol Pathol; 1995 Dec; 4(4):266-73. PubMed ID: 8634783 [TBL] [Abstract][Full Text] [Related]
3. Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy. Schiller JH; Adak S; Feins RH; Keller SM; Fry WA; Livingston RB; Hammond ME; Wolf B; Sabatini L; Jett J; Kohman L; Johnson DH J Clin Oncol; 2001 Jan; 19(2):448-57. PubMed ID: 11208838 [TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of p53 and ras p21 expression in nonsmall cell lung cancer. Fujino M; Dosaka-Akita H; Harada M; Hiroumi H; Kinoshita I; Akie K; Kawakami Y Cancer; 1995 Dec; 76(12):2457-63. PubMed ID: 8625071 [TBL] [Abstract][Full Text] [Related]
5. p53 mutations and overexpression affect prognosis of ovarian endometrioid cancer but not clear cell cancer. Okuda T; Otsuka J; Sekizawa A; Saito H; Makino R; Kushima M; Farina A; Kuwano Y; Okai T Gynecol Oncol; 2003 Mar; 88(3):318-25. PubMed ID: 12648581 [TBL] [Abstract][Full Text] [Related]
6. P53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus. Schneider PM; Stoeltzing O; Roth JA; Hoelscher AH; Wegerer S; Mizumoto S; Becker K; Dittler HJ; Fink U; Siewert JR Clin Cancer Res; 2000 Aug; 6(8):3153-8. PubMed ID: 10955797 [TBL] [Abstract][Full Text] [Related]
7. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance. Hsieh JS; Lin SR; Chang MY; Chen FM; Lu CY; Huang TJ; Huang YS; Huang CJ; Wang JY Am Surg; 2005 Apr; 71(4):336-43. PubMed ID: 15943410 [TBL] [Abstract][Full Text] [Related]
8. The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma. Izar B; Zhou H; Heist RS; Azzoli CG; Muzikansky A; Scribner EE; Bernardo LA; Dias-Santagata D; Iafrate AJ; Lanuti M J Thorac Oncol; 2014 Sep; 9(9):1363-9. PubMed ID: 25122432 [TBL] [Abstract][Full Text] [Related]
9. Comparative analysis of p53 gene mutations and protein accumulation in human non-small-cell lung cancer. Top B; Mooi WJ; Klaver SG; Boerrigter L; Wisman P; Elbers HR; Visser S; Rodenhuis S Int J Cancer; 1995 Apr; 64(2):83-91. PubMed ID: 7615358 [TBL] [Abstract][Full Text] [Related]
11. Implications and prognostic value of K-ras mutation for early-stage lung cancer in women. Nelson HH; Christiani DC; Mark EJ; Wiencke JK; Wain JC; Kelsey KT J Natl Cancer Inst; 1999 Dec; 91(23):2032-8. PubMed ID: 10580029 [TBL] [Abstract][Full Text] [Related]
12. Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer. Mitsudomi T; Oyama T; Kusano T; Osaki T; Nakanishi R; Shirakusa T J Natl Cancer Inst; 1993 Dec; 85(24):2018-23. PubMed ID: 8246288 [TBL] [Abstract][Full Text] [Related]
13. Mutations of p53 and K-ras genes as prognostic factors for non-small cell lung cancer. Huang CL; Taki T; Adachi M; Konishi T; Higashiyama M; Kinoshita M; Hadama T; Miyake M Int J Oncol; 1998 Mar; 12(3):553-63. PubMed ID: 9472092 [TBL] [Abstract][Full Text] [Related]
14. Trimodality treatment in Stage III nonsmall cell lung carcinoma: prrognostic impact of K-ras mutations after neoadjuvant therapy. Broermann P; Junker K; Brandt BH; Heinecke A; Freitag L; Klinke F; Berdel WE; Thomas M Cancer; 2002 Apr; 94(7):2055-62. PubMed ID: 11932909 [TBL] [Abstract][Full Text] [Related]
15. Analysis of K-ras codon 12 mutations and p53 overexpression in colorectal nodule-aggregating tumors. Kusaka T; Fukui H; Sano Y; Ueda Y; Chiba T; Fujimori T J Gastroenterol Hepatol; 2000 Oct; 15(10):1151-7. PubMed ID: 11106095 [TBL] [Abstract][Full Text] [Related]
16. Mutations of the EGFR and K-ras genes in resected stage I lung adenocarcinoma and their clinical significance. Ohba T; Toyokawa G; Kometani T; Nosaki K; Hirai F; Yamaguchi M; Hamatake M; Seto T; Ichinose Y; Sugio K Surg Today; 2014 Mar; 44(3):478-86. PubMed ID: 23609009 [TBL] [Abstract][Full Text] [Related]
17. K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer. Fukuyama Y; Mitsudomi T; Sugio K; Ishida T; Akazawa K; Sugimachi K Br J Cancer; 1997; 75(8):1125-30. PubMed ID: 9099959 [TBL] [Abstract][Full Text] [Related]
18. Prevalence and clinical significance of combined K-ras mutation and p53 aberration in pancreatic adenocarcinoma. Dergham ST; Dugan MC; Kucway R; Du W; Kamarauskiene DS; Vaitkevicius VK; Crissman JD; Sarkar FH Int J Pancreatol; 1997 Apr; 21(2):127-43. PubMed ID: 9209954 [TBL] [Abstract][Full Text] [Related]
19. Prognostic value of specific KRAS mutations in lung adenocarcinomas. Siegfried JM; Gillespie AT; Mera R; Casey TJ; Keohavong P; Testa JR; Hunt JD Cancer Epidemiol Biomarkers Prev; 1997 Oct; 6(10):841-7. PubMed ID: 9332768 [TBL] [Abstract][Full Text] [Related]
20. [Mutations of ras and p53 genes in human non-small cell lung cancer cell lines and their clinical significance]. Mitsudomi T; Oyama T; Gazdar AF; Minna JD; Okabayashi K; Shirakusa T Nihon Geka Gakkai Zasshi; 1992 Sep; 93(9):944-7. PubMed ID: 1361656 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]